MiniMed Group, Inc. (MMED) Competitive Analysis & Comparison (2026)

Quality vs Value comparison of MiniMed Group, Inc. (MMED) and competitors
Company	Ticker	Quality Score	Value Score	Classification
MiniMed Group, Inc.	MMED	60%	70%	High Quality
DexCom, Inc.	DXCM	100%	80%	High Quality
Insulet Corporation	PODD	93%	40%	Investable
Tandem Diabetes Care, Inc.	TNDM	33%	40%	Underperform
Beta Bionics, Inc.	BBNX	40%	30%	Underperform
Senseonics Holdings, Inc.	SENS	27%	20%	Underperform

MiniMed Group, Inc. (MMED) occupies a unique and transitional space within the specialized therapeutic devices sector. Following its March 2026 spin-off from its parent company Medtronic, MMED entered the public markets as a massive, fully-formed entity rather than a scrappy startup. It generated an impressive $3.1B in annual revenue for fiscal 2026, driven by its massive installed base of over 640,000 legacy insulin pump users and robust international sales. Unlike many of its competitors who specialize strictly in either continuous glucose monitors (CGMs) or insulin pumps, MMED's primary strategy revolves around an integrated, "full-stack" ecosystem where the hardware, sensors, and algorithmic software all operate seamlessly under one roof. However, the industry dynamic has shifted heavily toward interoperability in recent years. Patients and physicians increasingly prefer to mix and match the best available CGMs with the best available pumps, which has allowed agile, pure-play competitors to slowly chip away at MMED’s historical dominance. To combat this, MMED is rapidly expanding its portfolio with products like the MiniMed Flex and forming strategic partnerships (such as its dual-sensor collaboration with Abbott) to modernize its ecosystem and keep users locked into its platform. For an everyday retail investor, this sets up a classic turnaround narrative: MMED is defending a massive legacy moat against highly specialized, fast-moving disruptors. From a financial perspective, MMED's massive scale comes with significant baggage. Despite pulling in over $3B in top-line sales, the company posted a net loss of -$331M for the 2026 fiscal year. It is burdened by the friction of corporate restructuring, elevated operating costs, and intercompany debt. Comparing MMED to its peers requires balancing the safety of its massive global revenue footprint against its lack of bottom-line profitability. While market darlings like DexCom and Insulet command massive valuation premiums due to their high profit margins, MMED trades at a relative discount, offering potential upside only if its management can successfully execute their target of a 16% adjusted EBITDA margin by 2027.

DexCom is an absolute giant in the continuous glucose monitoring (CGM) space, boasting a market capitalization that heavily eclipses MMED's. DexCom's primary strength is its pure-play focus, which has made its sensors the global gold standard for accuracy and user experience. MMED, conversely, is attempting to defend an all-in-one ecosystem that relies on its own proprietary sensors. DexCom's major risk is increasing market saturation in the Type 1 diabetes space, but it is effectively countering this by expanding into the Type 2 market. MMED is structurally weaker in standalone sensor adoption compared to DXCM's ubiquitous platform. Contrasting Business & Moat, we look at brand (DXCM wins, as its name is virtually synonymous with modern CGMs), switching costs (MMED wins, because patients on a fully integrated pump system face higher hurdles to switch than those just using sensors), scale (DXCM wins effortlessly with a $29.11B market cap vs MMED's $4.34B), network effects (DXCM wins, supported by widespread app integration and data-sharing networks), regulatory barriers (Even, as both expertly navigate stringent FDA Class III device approvals), and other moats (DXCM wins on data-driven algorithmic IP). For concrete proof, DXCM's market rank stands at #1 in dedicated CGM adoption, whereas MMED relies on a 68% ecosystem attachment rate. Overall Business & Moat Winner: DXCM, because its brand ubiquity and dominant software ecosystem create an insurmountable moat in sensor technology. (Note: Scale is critical in finance because larger companies can negotiate better supply costs, leading to structurally higher profit margins). Diving into Financial Statement Analysis, revenue growth—which tells us how fast a business is expanding its sales—favors DXCM (20%) over MMED (14.2%). Gross/operating/net margin represent the layers of profitability from production down to the bottom line; DXCM's net margin of 12% crushes MMED's net loss margin of -10.6%, proving DXCM is far superior at turning sales into actual cash. ROE/ROIC measure a company's skill at generating profits from shareholder capital; DXCM wins at 15% compared to MMED's -9%. Liquidity, which tracks a firm's ability to cover immediate debts, favors DXCM at 2.5x vs MMED's 1.5x. Net debt/EBITDA shows bankruptcy risk relative to cash flow; DXCM is vastly safer at 0.5x vs MMED's estimated 3.5x. Interest coverage reveals how easily profits pay off debt interest; DXCM wins with an elite 20x against MMED's <0x. FCF/AFFO, showing actual cash left for investors, is superior at DXCM ($500M vs -$100M). Both tie on payout/coverage at 0% as neither pays dividends. Overall Financials Winner: DXCM, because it effortlessly blends high top-line expansion with elite, cash-generating margins. Looking at 1/3/5y revenue/FFO/EPS CAGR—which smooths out yearly volatility to reveal true annualized growth—DXCM wins with an EPS CAGR of 20%/25%/30% over the 2021-2026 period, dominating MMED's flat historical carve-out trend. The margin trend (bps change), measuring whether profitability is expanding or shrinking, favors DXCM (+500 bps vs -200 bps), making it the margins winner. TSR incl. dividends reflects the total stock return to shareholders; DXCM is the TSR winner, up +100% over 5 years, while MMED is down -22% since its March 2026 IPO. For risk metrics, we look at maximum historical drop and stock swing relative to the market; MMED has a max drawdown of -25% and volatility/beta of 1.2, compared to DXCM's -40% and 1.1. Despite a deeper past drawdown, DXCM's positive rating moves make it the risk winner. Overall Past Performance Winner: DXCM, as it has a documented history of compounding investor wealth that a newly listed spin-off simply cannot match. Contrasting Future Growth, TAM/demand signals (the total addressable market) give DXCM the edge by successfully targeting millions of non-insulin Type 2 diabetics. For pipeline & pre-leasing (measuring future product backlog), DXCM's Stelo OTC sensor rollout beats MMED's Flex pump launch. Yield on cost measures the return on new capital projects; DXCM has the edge with higher returns on its automated manufacturing expansion. Pricing power, or the ability to raise prices without losing customers, is marked even as both face strict health insurance reimbursement ceilings. Cost programs aimed at internal efficiency give MMED the edge as it aggressively trims post-IPO overhead. For the refinancing/maturity wall, tracking when large debts come due, DXCM has the edge with its cash-rich balance sheet. Finally, ESG/regulatory tailwinds are even, with both supported by global diabetes awareness initiatives. Overall Growth outlook winner: DXCM, supported by its rapid expansion into the massive Type 2 diabetes demographic. The primary risk to this view is sudden Medicare reimbursement cuts. Valuation requires looking through multiple lenses. P/E, showing the price paid per dollar of earnings, is 32.24x for DXCM while MMED is negative (losing money). EV/EBITDA, which compares total company value to core cash profits, is 25x for DXCM and negative for MMED. P/AFFO (using Price/FCF as a cash flow proxy) stands at 45x for DXCM vs a negative figure for MMED. The implied cap rate (FCF yield, estimating annual cash return on the stock price) favors DXCM at 2.5% compared to MMED's cash burn. The NAV premium/discount (Price/Book ratio) is 10x for DXCM and 2x for MMED. Both share a 0% dividend yield & payout/coverage. Quality vs price note: DXCM's steep premium is fully justified by its high-growth, cash-printing business model compared to MMED's turnaround status. Better value today: DXCM, because paying a premium for guaranteed cash flow is drastically less risky than betting on an unproven, unprofitable carve-out. Winner: DXCM over MMED. DexCom operates from a position of absolute fundamental superiority, boasting a $29.11B market cap, double-digit net margins, and massive brand dominance in the CGM space. MMED's key strengths lie in its massive legacy installed base of 640,000 users and a robust $3.1B revenue footprint, but its notable weaknesses—including a -10.6% net margin and negative free cash flow—highlight the massive friction of operating a legacy hardware ecosystem. The primary risks for MMED involve failing to successfully commercialize its new Flex systems while balancing heavy corporate debt. Ultimately, DXCM's proven profitability and market-leading innovation make it a vastly superior investment vehicle over the deeply challenged MMED.

Insulet Corporation represents the modern face of insulin delivery, heavily outperforming legacy systems with its tubeless Omnipod technology. While MMED relies on traditional, durable tubed pumps that require long-term commitments, Insulet utilizes a "pay-as-you-go" pharmacy model that is incredibly popular with new patients. Insulet's main weakness is its sole reliance on the pump form factor, exposing it to supply chain risks. However, its strengths in usability and patient acquisition make it fundamentally stronger than MMED, which is actively bleeding market share to Insulet's tubeless alternatives. Evaluating Business & Moat, we contrast brand (PODD wins, as Omnipod is the definitive leader in tubeless delivery), switching costs (MMED wins, because its durable hardware locks patients in for 4-year insurance cycles), scale (PODD wins with a $10.33B market cap vs MMED's $4.34B), network effects (Even, neither has a true network effect platform), regulatory barriers (Even, both require stringent FDA clearances), and other moats (PODD wins on manufacturing patents for miniaturized tubeless pumps). For concrete proof, PODD's customer retention is exceptional, taking the #1 market rank in new patient captures. Overall Business & Moat Winner: PODD, due to its highly disruptive, patent-protected tubeless technology. (Note: Switching costs act as a moat because they mathematically guarantee recurring revenue from locked-in patients). On Financial Statement Analysis, revenue growth—indicating market demand—favors PODD (20%) over MMED's 14.2%. Gross/operating/net margin track profitability; PODD wins with a 68% gross margin and positive net margin against MMED's -10.6% net loss. ROE/ROIC measure a company's skill at generating profits from its invested cash; PODD wins as it generates positive returns versus MMED's -9%. Liquidity, which tracks a firm's ability to cover immediate debts, favors PODD at 3.0x over MMED's 1.5x. Net debt/EBITDA shows debt risk relative to cash flow; PODD is vastly safer at 1.2x vs MMED's 3.5x. Interest coverage reveals how easily profits pay off debt interest; PODD wins with ample coverage against MMED's <0x. FCF/AFFO shows cash available to investors, where PODD's positive generation beats MMED's -$100M drain. Both tie on payout/coverage at 0%. Overall Financials Winner: PODD, because it has successfully scaled a high-margin recurring revenue model while MMED remains trapped in unprofitability. Reviewing 1/3/5y revenue/FFO/EPS CAGR—showing steady historical compounding—PODD wins with a 25%/30%/35% EPS CAGR over the 2021-2026 window, vastly outperforming MMED's negative EPS trajectory. The margin trend (bps change) favors PODD (+400 bps vs -200 bps), declaring it the margins winner. TSR incl. dividends measures total shareholder wealth creation; PODD is the TSR winner over 5 years despite a brutal 1-year drop of -55%, while MMED is down -22% since IPO. Looking at risk, MMED has a max drawdown of -25% and volatility/beta of 1.2, whereas PODD suffered a worse -60% max drawdown with a beta of 1.3. Due to the lower historical drop, MMED is the risk winner. Overall Past Performance Winner: PODD, because its long-term compounding of revenue and margins greatly outweighs its recent stock volatility. For Future Growth, TAM/demand signals favor PODD due to the rising adoption of tubeless pumps in the massive Type 2 market. Pipeline & pre-leasing (product backlog) gives PODD the edge with rapid international Omnipod 5 rollouts. Yield on cost measures the cash return on factory expansion; PODD has the edge through highly automated overseas manufacturing. Pricing power is even due to universal insurance ceilings. Cost programs give MMED the edge as it executes post-spinoff workforce optimizations. For the refinancing/maturity wall, PODD has the edge with a cleaner debt schedule. ESG/regulatory tailwinds are even. Overall Growth outlook winner: PODD, driven by its undeniable momentum in capturing new patients via the pharmacy channel. The main risk is intense upcoming competition from newer patch pumps. In Fair Value, P/E—the price per dollar of profit—is 34.72x for PODD while MMED is negative. EV/EBITDA, tracking total firm value against core cash flow, is 30x for PODD and negative for MMED. P/AFFO (Price/FCF) is 40x for PODD vs a negative metric for MMED. The implied cap rate (FCF yield) favors PODD at 1.8% compared to MMED's cash burn. The NAV premium/discount (Price/Book) is 12x for PODD and 2x for MMED. Both log a 0% dividend yield & payout/coverage. Quality vs price note: PODD trades at a steep growth premium, but it is justified by its dominant recurring revenue base compared to MMED's unproven turnaround. Better value today: PODD, as its established profitability offers a much safer floor than MMED's speculative recovery. Winner: PODD over MMED. Insulet is fundamentally superior across almost every financial and operational metric, boasting a $10.33B market cap and a highly profitable, recurring "pay-as-you-go" business model. MMED's primary strengths are its massive historical footprint of 640,000 users and a broad international distribution network, but its critical weaknesses—namely negative operating margins and reliance on legacy hardware—stunt its valuation. The primary risk for MMED is the continued patient exodus toward tubeless options like Omnipod. With robust cash generation and undeniable market momentum, PODD easily beats MMED as a long-term investment.

Tandem Diabetes Care is a direct, agile competitor to MMED in the durable insulin pump market. While MMED relies on a closed hardware-sensor ecosystem, Tandem successfully built its brand by partnering with DexCom and Abbott, offering patients the ultimate freedom of choice. Tandem's core strength is its superior, user-friendly software (Control-IQ), but its main weakness is its smaller scale and recent unprofitability. In this matchup, MMED represents the slow, lumbering giant with massive revenue, while Tandem represents the specialized, volatile disruptor. In Business & Moat, we evaluate brand (TNDM wins, beloved by patients for its touchscreen interfaces), switching costs (Even, both use 4-year durable pump warranties that lock patients in), scale (MMED wins easily with $3.1B in sales vs TNDM's $1.03B), network effects (Even, neither possesses true software network effects), regulatory barriers (Even, identical FDA hurdles), and other moats (MMED wins on global distribution infrastructure). For concrete proof, MMED boasts 640,000 users, easily dwarfing TNDM's installed base. Overall Business & Moat Winner: MMED, because its sheer global reach and massive installed base provide a structural safety net that Tandem lacks. (Note: A large installed base guarantees a steady stream of high-margin supply reorders, smoothing out volatile hardware sales). Reviewing Financial Statement Analysis, revenue growth—the pace of sales expansion—favors MMED (14.2%) over TNDM's sluggish 2%. Gross/operating/net margin track efficiency; both are losing money, but MMED's 65% gross margin demonstrates better baseline pricing power than TNDM's 56%. ROE/ROIC, evaluating return on invested cash, is heavily negative for both, resulting in a tie. Liquidity measures the ability to meet short-term obligations; TNDM wins with a stellar 3.58x current ratio compared to MMED's 1.5x. Net debt/EBITDA, assessing debt safety, favors MMED because TNDM's ratio sits at a dangerous 5.55x. Interest coverage, detailing the ease of paying interest, favors MMED as TNDM's ratio is deep in the red at -9.8x. FCF/AFFO, the true cash left for the business, is negative for both. Both record 0% on payout/coverage. Overall Financials Winner: MMED, as its massive $3.1B revenue base provides a stronger foundation for eventual profitability than TNDM's stalling top line. Comparing 1/3/5y revenue/FFO/EPS CAGR, MMED wins on revenue growth with a 14%/8%/5% historical trend over 2021-2026, beating TNDM's recent flattening. The margin trend (bps change) favors MMED (+100 bps vs TNDM's -300 bps), making it the margins winner. TSR incl. dividends tracks total returns; TNDM is the TSR loser, down -22% over 1 year and drastically down from its pandemic highs, while MMED is down -22% since its recent IPO. For risk, MMED has a max drawdown of -25% and volatility/beta of 1.2, whereas TNDM has suffered a devastating -80% max drawdown with a beta of 1.26. MMED is the undeniable risk winner. Overall Past Performance Winner: MMED, because TNDM's historical volatility and recent growth deceleration make it a far riskier asset. Looking at Future Growth, TAM/demand signals are even as both battle for the exact same Type 1 durable pump demographic. Pipeline & pre-leasing (measuring upcoming product momentum) gives TNDM the edge with its highly anticipated Tandem Mobi system. Yield on cost for manufacturing is even. Pricing power favors MMED due to its ability to bundle sensors and pumps together. Cost programs give MMED the edge as it enacts aggressive post-spinoff synergies. For the refinancing/maturity wall, MMED has the edge with longer-dated Medtronic-backed debt. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MMED, simply because its international footprint provides far more untapped growth avenues than TNDM's US-heavy concentration. The primary risk is Tandem stealing MMED's domestic users. In Fair Value, P/E is negative for both companies. EV/EBITDA is negative for both. P/AFFO (Price/FCF) is negative for both. Therefore, we must value them on sales. The implied cap rate (FCF yield) is non-applicable. The NAV premium/discount (measured here as Price/Sales) favors TNDM, which trades at a rock-bottom 1.2x sales compared to MMED's 1.4x. Both log a 0% dividend yield & payout/coverage. Quality vs price note: TNDM is priced like a distressed asset, while MMED is priced like a stable turnaround. Better value today: MMED, because paying a slightly higher sales multiple for a company with triple the revenue and a global distribution network is fundamentally safer. Winner: MMED over TNDM. While Tandem is praised for its agile software and interoperability, it has faltered financially, posting stagnant 2% growth and carrying a dangerous -9.8x interest coverage ratio. MMED leverages its massive $3.1B scale and 640,000 user base to absorb market shocks far better than its smaller rival. TNDM's primary weakness is its over-reliance on a single domestic product cycle, whereas MMED's international strength acts as a massive operational hedge. Because TNDM's balance sheet and growth trajectory have severely weakened, MMED stands out as the much safer, scale-driven investment in the durable pump space.

Ypsomed Holding AG is a powerhouse Swiss medical device company that operates largely behind the scenes, providing essential injection and infusion systems. Unlike MMED, which focuses heavily on a direct-to-consumer pump and sensor ecosystem, Ypsomed operates a highly lucrative B2B model, supplying customized pens and auto-injectors to global pharmaceutical companies, alongside its own diabetes care line. Ypsomed's fundamental strength is its elite European manufacturing efficiency, while MMED is bogged down by bloated corporate overhead. In Business & Moat, we evaluate brand (Ypsomed wins in the B2B pharma space as a premier supplier), switching costs (Ypsomed wins, as pharma companies face massive regulatory hurdles to swap out a drug delivery device once approved), scale (Even, with Ypsomed at a $5.1B market cap and MMED at $4.3B), network effects (Even, non-applicable to physical devices), regulatory barriers (Even, both face strict EMA/FDA approvals), and other moats (Ypsomed wins on precision manufacturing IP). For concrete proof, Ypsomed's manufacturing contracts secure multi-year locked revenues with top-tier pharma giants. Overall Business & Moat Winner: Ypsomed, because embedding its devices directly into pharmaceutical supply chains creates an incredibly durable, low-churn revenue stream. (Note: B2B switching costs are often much stronger moats than consumer preferences). Reviewing Financial Statement Analysis, revenue growth favors MMED (14.2%) over Ypsomed (12%). However, gross/operating/net margin track actual business quality; Ypsomed crushes MMED with an elite 33.6% operating margin and massive positive net income (CHF 221M), against MMED's heavy losses. ROE/ROIC, evaluating capital efficiency, easily goes to Ypsomed with a staggering 31% ROE versus MMED's -9%. Liquidity, which tracks current assets to liabilities, favors Ypsomed at 1.07x against MMED's 1.5x (MMED wins liquidity). Net debt/EBITDA, assessing debt safety, favors Ypsomed with low leverage compared to MMED's 3.5x. Interest coverage, detailing the ease of paying interest, is an elite 76.55x for Ypsomed versus MMED's <0x. FCF/AFFO shows cash available to investors, where Ypsomed's positive cash flow obliterates MMED. For payout/coverage, Ypsomed wins as it pays a 0.6% dividend, while MMED pays 0%. Overall Financials Winner: Ypsomed, as it operates a spectacularly profitable, high-margin business compared to MMED's cash-burning operations. Looking at 1/3/5y revenue/FFO/EPS CAGR, Ypsomed wins cleanly with a soaring EPS CAGR across the 2021-2026 window, growing earnings from CHF 3.82 to CHF 16.30. The margin trend (bps change) favors Ypsomed (+300 bps), declaring it the margins winner. TSR incl. dividends measures total wealth creation; Ypsomed is the TSR winner, up a massive +128% over 5 years, while MMED is down -22% since IPO. For risk, MMED has a max drawdown of -25% and volatility/beta of 1.2, whereas Ypsomed has a low beta of 0.78. Ypsomed is the risk winner due to its highly stable stock profile. Overall Past Performance Winner: Ypsomed, showcasing a flawless track record of compounding European capital. Contrasting Future Growth, TAM/demand signals favor Ypsomed, which is riding the massive global explosion of GLP-1 weight-loss drugs that require their auto-injectors. Pipeline & pre-leasing (future product backlog) gives Ypsomed the edge with guaranteed pre-orders from massive pharma clients. Yield on cost measures the return on factory capital; Ypsomed has the edge after doubling its tool shop capacity. Pricing power favors Ypsomed in the B2B space. Cost programs give Ypsomed the edge as it localizes manufacturing. For the refinancing/maturity wall, Ypsomed has the edge with abundant cash flow. ESG/regulatory tailwinds are even. Overall Growth outlook winner: Ypsomed, as its exposure to the GLP-1 auto-injector megatrend provides a massive, de-risked runway for growth. The main risk is a sudden shift to oral GLP-1 medications. In Fair Value, P/E is a highly reasonable 17.33x for Ypsomed while MMED is negative. EV/EBITDA is 14.59x for Ypsomed and negative for MMED. P/AFFO (Price/FCF) sits at 18.6x for Ypsomed vs a negative metric for MMED. The implied cap rate (FCF yield) favors Ypsomed at ~5.3% compared to MMED's cash burn. The NAV premium/discount (Price/Book) is 6.18x for Ypsomed and 2x for MMED. Ypsomed wins dividend yield & payout/coverage at 0.62%. Quality vs price note: Ypsomed is objectively cheap for a company with 31% ROE, whereas MMED's low multiple reflects actual financial distress. Better value today: Ypsomed, offering world-class profitability at a value-stock multiple. Winner: Ypsomed over MMED. Ypsomed is a masterclass in medical device manufacturing, boasting a pristine 76.5x interest coverage ratio, incredible B2B switching costs, and booming exposure to the auto-injector market. MMED is bogged down by its direct-to-consumer pump legacy, failing to generate positive EPS while carrying a massive corporate infrastructure. MMED's main strength is its global revenue size, but its glaring weakness is its inability to turn those sales into net profits. For investors seeking safe, compounding capital with a dividend, Ypsomed is fundamentally superior to the speculative, cash-burning MMED.

Beta Bionics represents the bleeding edge of specialized therapeutic devices, having developed the iLet Bionic Pancreas—a system designed to remove almost all mathematical burden from the patient. While MMED relies on complex algorithms that still require heavy user input (like carb counting), Beta Bionics aims for total automation. However, BBNX is a recent upstart with a tiny $618M market cap, battling severe cash burn and manufacturing growing pains. MMED represents stable global scale, whereas BBNX is a high-risk, high-reward pure technology play. Evaluating Business & Moat, we contrast brand (MMED wins, having a globally recognized 40-year legacy), switching costs (Even, both utilize locked-in durable hardware cycles), scale (MMED wins dominantly with $3.1B in sales vs BBNX's $110M run rate), network effects (Even, non-applicable), regulatory barriers (Even, both clear strict FDA pathways), and other moats (BBNX wins on autonomous algorithmic IP). For concrete proof, MMED operates in 80 countries, dwarfing BBNX's highly concentrated US footprint. Overall Business & Moat Winner: MMED, because global distribution networks and established payer contracts take decades to build and cannot be easily replicated by a micro-cap startup. (Note: Global scale acts as a moat because it allows a company to absorb localized regulatory shocks). On Financial Statement Analysis, revenue growth—the ultimate proof of product adoption—heavily favors BBNX at 57% compared to MMED's 14.2%. However, gross/operating/net margin track the true cost of that growth; MMED's 65% gross margin beats BBNX's 59.5%, and MMED's operating losses are far less severe than BBNX's catastrophic -64% EBITDA margin. ROE/ROIC, evaluating capital efficiency, is deeply negative for both (Tie). Liquidity, which tracks current assets to liabilities, favors BBNX due to its $239.5M cash pile from recent fundraising. Net debt/EBITDA assesses debt safety; BBNX wins because it holds essentially zero debt, funding itself via equity. Interest coverage favors BBNX (no interest) over MMED (<0x). FCF/AFFO shows cash burn; MMED loses less on a percentage basis, making it the winner. Both tie on payout/coverage at 0%. Overall Financials Winner: MMED, because while BBNX is growing faster, its fundamental unit economics are currently bleeding too much cash to be considered financially stable. Looking at 1/3/5y revenue/FFO/EPS CAGR, BBNX wins the growth category with explosive recent revenue momentum over the 2024-2026 period, beating MMED's 8% organic rate. The margin trend (bps change) favors BBNX (+864 bps gross margin improvement), making it the margins winner. TSR incl. dividends measures total returns; both have struggled, but BBNX is the TSR loser, down -20% over the last year, similar to MMED's -22%. For risk, MMED has a max drawdown of -25% and volatility/beta of 1.2, whereas BBNX is a highly volatile micro-cap prone to massive swings. MMED is the undeniable risk winner. Overall Past Performance Winner: MMED, because BBNX's extreme volatility and FDA warning letter history make it a highly speculative asset. Contrasting Future Growth, TAM/demand signals favor BBNX, as its "zero-input" algorithm appeals heavily to needle-phobic or math-weary diabetics. Pipeline & pre-leasing (product backlog) gives MMED the edge with its diversified Flex and Go releases. Yield on cost is even. Pricing power favors MMED, which can bundle hardware and sensors. Cost programs give MMED the edge as it scales down overhead, while BBNX is forced to spend heavily to acquire new users. For the refinancing/maturity wall, BBNX has the edge with no major debt. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MMED, because it has the infrastructure to actually fulfill global demand without destroying its balance sheet. The main risk to BBNX is running out of cash before reaching scale. In Fair Value, P/E is negative for both companies. EV/EBITDA is negative for both. P/AFFO (Price/FCF) is negative for both. The implied cap rate (FCF yield) is non-applicable. The NAV premium/discount (Price/Sales) favors MMED at 1.4x compared to BBNX's expensive 5.6x trailing sales. Both log a 0% dividend yield & payout/coverage. Quality vs price note: BBNX is priced strictly on aggressive hyper-growth speculation, while MMED is priced as a mature, albeit struggling, incumbent. Better value today: MMED, because its rock-bottom valuation provides a much safer floor than betting on a cash-burning micro-cap. Winner: MMED over BBNX. Beta Bionics has undeniably superior algorithm technology, evidenced by its 57% revenue growth, but it operates with terrifyingly poor unit economics, sporting an adjusted EBITDA margin of -64%. MMED leverages its massive $3.1B revenue base and gross margins of 65% to fund its turnaround. BBNX's primary weakness is its existential need to constantly raise capital to survive, coupled with recent FDA quality management warnings. For a retail investor, MMED is simply a much safer, lower-risk vehicle to gain exposure to the diabetes tech space.

Senseonics Holdings operates on the fringes of the continuous glucose monitoring market with its Eversense system, the only long-term implantable CGM. MMED, by contrast, focuses on external, short-wear hardware. Senseonics is a micro-cap company ($382M market cap) attempting to carve out a niche for patients who hate replacing sensors every 10-14 days. MMED’s absolute strength is its massive scale and global distribution, while Senseonics’ fatal weakness is its complete lack of profitability and microscopic market share. In Business & Moat, we evaluate brand (MMED wins, a household name in diabetes care), switching costs (SENS wins, because a surgically implanted sensor is incredibly difficult for a patient to casually swap out), scale (MMED wins in a landslide, $4.34B vs $382M), network effects (Even, non-applicable), regulatory barriers (SENS wins, as implantable devices face vastly stricter FDA scrutiny, protecting them from copycats), and other moats (MMED wins on global payer contracts). For concrete proof, MMED is active in 80 countries, whereas SENS has struggled to gain basic insurance reimbursement for its procedures. Overall Business & Moat Winner: MMED, because an implantable moat is useless if you cannot achieve the scale necessary to survive. (Note: Regulatory barriers act as a moat by preventing cheap knock-offs from flooding the market). On Financial Statement Analysis, revenue growth favors SENS at an eye-popping 71.8% quarter-over-quarter, beating MMED's 14.2%. However, gross/operating/net margin track true business viability; MMED's 65% gross margin easily defeats SENS, which operates at a disastrous -146.8% operating margin. ROE/ROIC, evaluating capital efficiency, is deeply negative for both, but SENS is worse at -168.3% (MMED wins). Liquidity, which tracks current assets to liabilities, favors SENS due to a recent $92M equity raise. Net debt/EBITDA assesses debt safety; SENS wins by relying on equity dilution rather than debt. Interest coverage favors SENS (no interest) over MMED (<0x). FCF/AFFO shows cash burn; MMED loses far less on a percentage basis, making it the winner. Both tie on payout/coverage at 0%. Overall Financials Winner: MMED, because SENS is fundamentally broken at the operating level, burning more cash than it generates in revenue. Comparing 1/3/5y revenue/FFO/EPS CAGR, SENS wins on pure top-line percentage growth over the 2021-2026 window due to starting from a near-zero base. The margin trend (bps change) favors MMED, as SENS continues to plunge further into the red, making MMED the margins winner. TSR incl. dividends measures total returns; SENS is the TSR loser, continually diluting shareholders to survive, while MMED is down -22% since IPO. For risk, MMED has a max drawdown of -25% and volatility/beta of 1.2, whereas SENS has wiped out massive amounts of shareholder value historically and relies on constant stock offerings. MMED is the undeniable risk winner. Overall Past Performance Winner: MMED, avoiding the extreme wealth-destruction seen in SENS's long-term chart. Contrasting Future Growth, TAM/demand signals favor MMED, as the mass market overwhelmingly prefers non-invasive external sensors over SENS's minor surgical implants. Pipeline & pre-leasing (product backlog) gives SENS the edge with its highly anticipated 365-day sensor. Yield on cost is even. Pricing power favors MMED, which commands standard reimbursement rates. Cost programs give MMED the edge as it trims post-IPO fat. For the refinancing/maturity wall, SENS has the edge by surviving on equity, but at the cost of massive shareholder dilution. ESG/regulatory tailwinds are even. Overall Growth outlook winner: MMED, because the implantable CGM market remains a tiny, unproven niche compared to the mainstream adoption of MMED's external products. The primary risk to SENS is continued shareholder dilution. In Fair Value, P/E is negative for both companies. EV/EBITDA is negative for both. P/AFFO (Price/FCF) is negative for both. The implied cap rate (FCF yield) is non-applicable. The NAV premium/discount (Price/Sales) favors MMED at 1.4x compared to SENS's massive 10.8x multiple. Both log a 0% dividend yield & payout/coverage. Quality vs price note: SENS is egregiously overpriced relative to its microscopic revenue and heavy cash burn. Better value today: MMED, offering a real, $3.1B business at a fraction of the sales multiple applied to SENS. Winner: MMED over SENS. Senseonics is a speculative micro-cap struggling to survive, plagued by a -146.8% operating margin and constant shareholder dilution. MMED easily dominates this matchup through overwhelming scale, bringing in $3.1B in annual revenue and leveraging a massive global distribution framework. SENS's only notable strength is its unique implantable technology, but its fatal weakness is an inability to commercialize it profitably without repeatedly tapping the equity markets. For retail investors, MMED is a fundamentally sounder business, while SENS functions more like a high-risk lottery ticket.

MiniMed Group, Inc. (MMED) Competitive Analysis

Executive Summary

Comprehensive Analysis

Competitor Details

DexCom, Inc.

Insulet Corporation

Tandem Diabetes Care, Inc.

Ypsomed Holding AG

Beta Bionics, Inc.

Senseonics Holdings, Inc.